Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TRK-950,Ramucirumab,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Bolt Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Bolt Biotherapeutics Updates Cancer Immunotherapy Co-Development with Toray
Details : The collaboration aims to develop TRK-950, an Caprin-1 designed to target multiple solid tumor types. Currently, it is being evaluated for the treatment of gastric cancer.
Product Name : TRK-950
Product Type : Antibody
Upfront Cash : Undisclosed
February 11, 2025
Lead Product(s) : TRK-950,Ramucirumab,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Bolt Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Immunis
Deal Size : Undisclosed
Deal Type : Partnership
Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
Details : The partnership aims to focus on the clinical development of TRK-820 (nalfurafine hydrochloride), which is being evaluated for the treatment of Uremic Pruritus.
Product Name : TRK-820
Product Type : Small molecule
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : Nalfurafine
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Immunis
Deal Size : Undisclosed
Deal Type : Partnership
Reset All
